A. Vergnenègre

机构：Hôpital Dupuytren · ORCID：0000-0002-5356-6070

发表论文 448 篇 · 总被引 17097 次 · h-index 40

代表论文

• First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial (2021 · Journal of Thoracic Oncology · 被引 324)
• Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC (2021 · Journal of Thoracic Oncology · 被引 210)
• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024 · Journal of Clinical Oncology · 被引 126)
• Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study (2024 · Journal of Clinical Oncology · 被引 124)
• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2023 · Annals of Oncology · 被引 99)
• A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis (2021 · Kidney International · 被引 83)